These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

951 related items for PubMed ID: 16152754

  • 21. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 22. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Apr; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 23. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 24. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 25. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI, Aboulhab J.
    HIV Med; 2005 Jan 13; 6(1):13-20. PubMed ID: 15670247
    [Abstract] [Full Text] [Related]

  • 26. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
    Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E, GESIDA 3903 Team.
    Clin Infect Dis; 2008 Oct 15; 47(8):1083-92. PubMed ID: 18781872
    [Abstract] [Full Text] [Related]

  • 27. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D, OzCombo 2 investigators.
    HIV Clin Trials; 2002 Oct 15; 3(3):177-85. PubMed ID: 12032876
    [Abstract] [Full Text] [Related]

  • 28. Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.
    Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM.
    Antivir Ther; 2002 Dec 15; 7(4):283-7. PubMed ID: 12553483
    [Abstract] [Full Text] [Related]

  • 29. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
    Bongiovanni M, Gianotti N, Chiesa E, Nasta P, Cicconi P, Capetti A, di Biagio A, Matti A, Tirelli V, Marconi P, de Luca A, Mussini C, Gatti F, Zaccarelli M, Abeli C, Torti C, Antinori A, Castagna A, d'Arminio Monforte A.
    Infection; 2007 Dec 15; 35(6):451-6. PubMed ID: 18034204
    [Abstract] [Full Text] [Related]

  • 30. A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
    Fox Z, Dragsted UB, Gerstoft J, Phillips AN, Kjaer J, Mathiesen L, Youle M, Katlama C, Hill A, Bruun JN, Clumeck N, Dellamonica P, Lundgren JD, COLATE study group.
    Antivir Ther; 2006 Dec 15; 11(6):761-70. PubMed ID: 17310820
    [Abstract] [Full Text] [Related]

  • 31. Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
    Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A.
    Antivir Ther; 1998 Dec 15; 3 Suppl 4():55-6. PubMed ID: 10723511
    [Abstract] [Full Text] [Related]

  • 32. Once-daily dosing of nevirapine in HAART.
    Clotet B.
    J Antimicrob Chemother; 2008 Jan 15; 61(1):13-6. PubMed ID: 18006524
    [Abstract] [Full Text] [Related]

  • 33. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L, Cargnel A, Soranzo ML, Chirianni A, Ferraro T, Di Stefano M, Angarano G.
    Antivir Ther; 1999 Jan 15; 4(4):195-202. PubMed ID: 10723498
    [Abstract] [Full Text] [Related]

  • 34. Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
    Jayaweera DT, Kolber MA, Brill M, Tanner T, Campo R, Rodriguez A, Chu HM, Garg V.
    HIV Med; 2004 Sep 15; 5(5):364-70. PubMed ID: 15369512
    [Abstract] [Full Text] [Related]

  • 35. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, ANRS 109 VISTA Study Group.
    Antivir Ther; 2006 Sep 15; 11(7):889-99. PubMed ID: 17302251
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S.
    Pediatrics; 2007 Oct 15; 120(4):e856-61. PubMed ID: 17846147
    [Abstract] [Full Text] [Related]

  • 37. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
    Eshleman SH, Krogstad P, Jackson JB, Wang YG, Lee S, Wei LJ, Cunningham S, Wantman M, Wiznia A, Johnson G, Nachman S, Palumbo P.
    J Infect Dis; 2001 Jun 15; 183(12):1732-8. PubMed ID: 11372025
    [Abstract] [Full Text] [Related]

  • 38. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M, AVANTI Study Group.
    Antivir Ther; 2001 Jun 15; 6(2):127-34. PubMed ID: 11491417
    [Abstract] [Full Text] [Related]

  • 39. Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
    Rajesh L, Karunaianantham R, Narayanan PR, Swaminathan S.
    AIDS Res Hum Retroviruses; 2009 Nov 15; 25(11):1179-85. PubMed ID: 19895208
    [Abstract] [Full Text] [Related]

  • 40. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.
    HIV Med; 2005 Sep 15; 6(5):353-9. PubMed ID: 16156884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.